Jacques Benoit lecture: the neuroendocrine view of the angiotensin and apelin systems

Journal of Neuroendocrinology
Catherine Llorens-Cortes, Claude Kordon

Abstract

The hyperactivity of the brain renin-angiotensin system (RAS) has been implicated in the development and maintenance of hypertension in several types of experimental and genetic hypertension animal models. Among the main bioactive peptides of the brain RAS, angiotensin (Ang) II and Ang III display the same affinity for type 1 and type 2 Ang II receptors. Both peptides, injected intracerebroventricularly, similarly increase arginine vasopressin (AVP) release and blood pressure (BP); however, because Ang II is converted in vivo to Ang III, the identity of the true effector is unknown. We review new insights into the predominant role of brain Ang III in the control of BP, underlining the fact that brain aminopeptidase A (APA), the enzyme generating brain Ang III, may therefore be an interesting candidate target for the treatment of hypertension. This justifies the development of potent systemically active APA inhibitors, such as RB150, as prototypes of a new class of antihypertensive agents for the treatment of certain forms of hypertension. We also searched for a putative angiotensin receptor subtype specific for Ang III and isolated a seven transmembrane-domain G protein-coupled receptor corresponding to the receptor for apelin,...Continue Reading

References

Apr 1, 1977·Proceedings of the Royal Society of London. Series B, Containing Papers of a Biological Character·D A PoulainR E Dyball
Apr 3, 1992·Journal of Medicinal Chemistry·M C Fournié-ZaluskiB P Roques
May 1, 1992·Endocrine Reviews·J M Saavedra
Feb 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·Q WuM D Cooper
Jan 1, 1990·Health Care for Women International·E J Saunders, J A Saunders
May 30, 1989·Biochemical and Biophysical Research Communications·B MalfroyR Hellmiss
Jan 1, 1987·Annual Review of Physiology·M I Phillips
Apr 1, 1986·Journal of Neurochemistry·J W HardingJ W Wright
Nov 1, 1985·The American Journal of Physiology·S TripathiE L Boulpaep
Jan 25, 1980·Science·M J BrownsteinH Gainer
Apr 29, 1994·Journal of Medicinal Chemistry·E N ChauvelM C Fournié-Zaluski
Mar 1, 1996·Hypertension·D B AverillC M Ferrario
Apr 12, 1996·The Journal of Biological Chemistry·G VazeuxC Llorens-Cortès
Apr 15, 1996·Annals of Internal Medicine·D R Saine, E R Ahrens
Jul 9, 1996·Proceedings of the National Academy of Sciences of the United States of America·D A DentonR S Weisinger
Apr 1, 1997·Physiological Reviews·J GutkowskaS M McCann
May 1, 1997·Journal of Hypertension·G BakrisH Gavras
Nov 25, 1997·Brain Research. Brain Research Reviews·J W Wright, J W Harding
Oct 30, 1998·Biochemical and Biophysical Research Communications·K TatemotoM Fujino
Dec 31, 1998·Journal of Neuroendocrinology·M Ludwig

❮ Previous
Next ❯

Citations

Apr 27, 2012·Pflügers Archiv : European journal of physiology·John W Wright, Joseph W Harding
Jan 13, 2009·General and Comparative Endocrinology·R Elwyn IsaacAlan D Shirras
Nov 19, 2008·Journal of Neurochemistry·Huijing Xia, Eric Lazartigues
Jul 6, 2014·Molecular Biology Reports·Di WuLinxi Chen
Mar 12, 2021·Journal of Medicinal Chemistry·Sanju NarayananRangan Maitra

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.